CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75907G
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Western Blot
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Monoclonal Human IgG1 kappa Clone # hu5c8 (Ruplizumab)
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human CD40L
Specificity
The antibody binds to CD40L with an IC50 of 0.845 ug/ml.
Clonality
Monoclonal
Host
Human
Isotype
IgG1 kappa
Applications for CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [DyLight 488]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD40 Ligand/TNFSF5
Alternate Names
CD154, CD40L, CD40LG, gp39, TNFSF5, TRAP
Gene Symbol
CD40LG
Additional CD40 Ligand/TNFSF5 Products
Product Documents for CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [DyLight 488]
Product Specific Notices for CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...